SNGX Soligenix, Inc.
Listings ·
At its September 17, 2026 annual meeting, stockholders approved a reverse split at a ratio of 1-for-2 to 1-for-20 and raised authorized common shares from 75,000,000 to 125,000,000.
Soligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,500,000.
Nasdaq told Soligenix on June 10, 2026 that its stock has closed below the $1.00 minimum bid price, and the company has until December 7, 2026 to regain compliance. Its board then ended the HyBryte development program, after an interim analysis in a Phase 3 trial recommended stopping it for futility.
Soligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,956,000.
After an interim efficacy analysis, the Data Monitoring Committee recommended stopping the Phase 3 HyBryte trial for futility, and Soligenix says it has approximately $5.9 million of cash.
Nasdaq told Soligenix on November 18, 2025 that the matter is closed. The company reported stockholders' equity of $7,597,976 for the quarter ended September 30, 2025, against a $2,500,000 requirement.
The offering covers 5,555,560 shares or equivalents with matching five-year warrants. Soligenix also cut the exercise price on 1,162,064 older warrants to $1.35.
Soligenix reported stockholders' equity of $1,828,951 at June 30, 2025 and has until September 29, 2025 to submit a plan to regain compliance with the Nasdaq minimum.
Soligenix, Inc. is a late-stage biopharmaceutical company developing and commercializing products for rare diseases with unmet medical need. It has two business segments. Specialized BioTherapeutics is developing HyBryte, a proposed name for synthetic hypericin, as a photodynamic therapy for cutaneous T-cell lymphoma. The first Phase 3 FLASH study reported positive primary endpoint results, and enrollment in a second Phase 3 study, FLASH2, began in December 2024, with top-line results anticipated in the second half of 2026. This segment also develops synthetic hypericin for psoriasis and dusquetide for aphthous ulcers in Behçet's Disease and for oral mucositis in head and neck cancer. Public Health Solutions develops RiVax, a ricin toxin vaccine candidate, a therapeutic candidate for emerging infectious diseases, filovirus vaccine programs and CiVax for COVID-19, using its ThermoVax heat stabilization platform. Development has been supported by government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.
| Product or program | What it is | Stage |
|---|---|---|
| HyBryte (synthetic hypericin) | Photodynamic therapy using topical synthetic hypericin for cutaneous T-cell lymphoma | Second Phase 3 (FLASH2) enrolling; top-line results anticipated in the second half of 2026 |
| SGX302 | Synthetic hypericin expansion for mild-to-moderate psoriasis | Phase 2a ongoing |
| SGX945 (dusquetide) | Innate Defense Regulator for aphthous ulcers in Behçet's Disease | Phase 2a complete |
| SGX942 (dusquetide) | Innate Defense Regulator for oral mucositis in head and neck cancer | Second Phase 3 needed; contingent on identifying a partner |
| RiVax | Ricin toxin vaccine candidate | Phase 1a, 1b and 1c trials completed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $119,371 | |
| Research and development | $7.5 million | $5.2 million |
| Net income (loss) | -$11.1 million | -$8.3 million |
| Cash from operations | -$10.3 million | -$8.4 million |
| Cash and equivalents | $7.9 million | $7.8 million |
Our latest story on this, dated Sep 17, 2026: "Soligenix stockholders approve reverse split authority and share increase". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 26, 2026: "Soligenix adds $2,500,000 to its at-the-market sales agreement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 15, 2025: "Soligenix gets Nasdaq notice for stockholders' equity below $2,500,000". The story links the filing or release it is based on. Read the story.
Soligenix, Inc. trades under the ticker SNGX on NASDAQ.
Soligenix, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0A6I.
The SEC Central Index Key (CIK) for Soligenix, Inc. is 812796. Its filings are on SEC EDGAR.
21,765,479 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Soligenix, Inc. under United States.
Our directory classifies Soligenix, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Soligenix, Inc. is US8342236044.
aibio.space lists Soligenix, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Soligenix, Inc. is a late-stage biopharmaceutical company developing and commercializing products for rare diseases with unmet medical need. It has two business segments.
HyBryte (synthetic hypericin): Photodynamic therapy using topical synthetic hypericin for cutaneous T-cell lymphoma Stage: Second Phase 3 (FLASH2) enrolling; top-line results anticipated in the second half of 2026.
SGX302: Synthetic hypericin expansion for mild-to-moderate psoriasis Stage: Phase 2a ongoing.
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio